Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is well positioned to capture market share with its innovative drug technology platform, strong regulatory support and potential for a non-dilutive financing opportunity. The company's pipeline shows promising results, with expected milestones in regulatory meetings, initiation of a global Phase 3 trial and potential accelerated approvals in the second half of 2026. However, there are some risks to consider, such as regulatory and financial risks, as well as competition in the market.

Bears say

OS Therapies is heavily focused on developing OST-HER2, their lead drug, for pulmonary metastatic osteosarcoma, a rare and aggressive cancer. With Phase 3 trials expected to launch in 2026 and potential accelerated approval pathways, the company may see market entry in the second half of the year. Despite their promising drug development, the company's current financials indicate a significant risk for investors with a heavy reliance on future success of OST-HER2.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.